站在仙林大学城迈向国际一流科学城的新起点，栖霞区将持续深化"政策赋能、平台搭桥、龙头引领"三 位一体技术转移体系，进一步优化政策供给、提升"霞科行"平台服务效能、强化标杆企业带动作用，加 快打通教育、科技、人才与产业深度融合的转化通道，让更多科研成果在栖霞落地生根、开花结果，为 全区乃至全市高质量发展注入源源不断的创新动能。 扬子晚报网2月24日讯（通讯员 栖宣 记者 张可）近日，南京市科学技术局正式下达2025年度市技术转 移奖励资金获奖名单，栖霞区共35家单位上榜，累计获得奖补资金155.75万元，排全市第二。此前获 评"2025年度栖霞区科技成果转化十佳单位"的南京正大天晴制药有限公司、中国电子科技集团公司第二 十八研究所等多家主体同步斩获市级奖励，实现"区级标杆"向"市级先进"的跨越，用实绩诠释了栖霞创 新担当。 技术转移是打通科技成果转化"最后一公里"的关键环节，市技术转移奖励资金的设立与发放，旨在深入 实施创新驱动发展战略，完善技术转移体系建设，激励各类主体积极投身科技成果扩散、流动与应用， 为全市科技创新高质量发展注入动能。 | | 2025 年度栖霞区科技成果转化"十佳单位" | | --- ...

Corcept Therapeutics (NasdaqCM:CORT) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Company ParticipantsAtabak Mokari - CFOBill Guyer - Chief Development OfficerCharlie Robb - Chief Business OfficerJing He - Equity Research AssociateJoe Belanoff - CEORoberto Vieira - President of OncologySean Maduck - President of EndocrinologyConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystSwayampakula Ramakanth - Managing Director and Senior Healthcare Equity Research Analyst ...

Corcept Therapeutics (NasdaqCM:CORT) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Company ParticipantsAtabak Mokari - CFOCharles Robb - Chief Business OfficerJing He - Equity Research AssociateJoe Belanoff - CEORoberto Vieira - President of OncologySean Maduck - President of EndocrinologyWilliam Guyer - Chief Development OfficerConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystSwayampakula Ramakanth - Managing Director and Senior Healthcare Equity Research Anal ...

Corcept Therapeutics (NasdaqCM:CORT) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Speaker5Thank you for standing by, and welcome to Corcept Therapeutics' fourth quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. To remove yourself from the queue, you may press star one one again. I would ...

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. for alleged misleading statements and failure to disclose critical information regarding its CELLECTRA device and the INO-3107 Biologics License Application [2][5]. Allegation Details - The lawsuit claims that during the Class Period, Inovio made false statements about the manufacturing quality of its CELLECTRA device, which impacted the likelihood of submitting the INO-3107 BLA to the FDA by the second half of 2024 [5]. - It is alleged that Inovio lacked sufficient information to support the eligibility of the INO-3107 BLA for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5]. - The lawsuit asserts that when the true information became public, investors suffered financial damages, particularly after the FDA's announcement regarding the BLA's acceptance on a standard review timeline rather than accelerated approval [5]. Stock Price Impact - Following the FDA's announcement on December 29, 2025, Inovio's stock price dropped by $0.56 per share, representing a decline of 24.45%, closing at $1.73 per share [5].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）子公司于近日收到国家药品监督管理局下发 的关于复方聚乙二醇（3350）电解质口服溶液获批注册的药品注册证书，现将有关情况公告如下： 一、 药物的基本情况 7、药品批准文号：国药准字H20263376 8、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要 求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所附执行。本品应在药品生 产质量管理规范符合性检查通过后方可上市。 三、备查文件 1、复方聚乙二醇（3350）电解质口服溶液药品注册证书。 特此公告。 葵花药业集团股份有限公司 董事会 2026年2月24日 建议上市后考察并选择乙醛控制更严格的原料药，进一步提升制剂质量。 9、适应症：治疗慢性便秘、粪便嵌塞。 10、上市许可持有人及生产企业：葵花药业集团（唐山）生物制药有限公司 二、风险提示 复方聚乙二醇（3350）电解质口服溶液取得《药品注册证书》，将为公 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - Febru ...

Supernus Pharmaceuticals (NasdaqGM:SUPN) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsJack A. Khattar - President and CEOPeter Vozzo - Managing DirectorTim Dec - CFONone - Company RepresentativeConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystJon Cox - AnalystKristen Kluska - AnalystPavan Patel - Biopharma Equity Research AnalystStacy Ku - AnalystOperatorGood afternoon. Welcome to Supernus Pharmaceuticals for the quarter and full year 2025 ...

BridgeBio (NasdaqGS:BBIO) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAdi Jayaraman - Senior Managing DirectorAndrew Tsai - Managing DirectorChinmay Shukla - SVP of Strategic FinanceJustin To - CEO of Skeletal DysplasiasMatt Outten - Chief Commercial OfficerNeil Kumar - CEOTom Trimarchi - President and CFOConference Call ParticipantsBiren Amin - Managing Director and Investment Analyst in Life SciencesEliana Merle - Senior Biotech Equity Research AnalystMani Foroohar - Senior Man ...

Supernus Pharmaceuticals (NasdaqGM:SUPN) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsJack A. Khattar - President and CEOPeter Vozzo - Managing DirectorTim Dec - CFONone - Company RepresentativeConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystJon Cox - AnalystKristen Kluska - AnalystPavan Patel - Biopharma Equity Research AnalystStacy Ku - AnalystOperatorGood afternoon. Welcome to Supernus Pharmaceuticals for the quarter and full year 2025 ...